Oxford Science Enterprises is an independent investment company that finds, funds, and builds transformational science and technology companies emerging from Oxford research.
Amadeus Capital Partners and Oxford Science Enterprises led the pre-seed round to accelerate the deployment of the robotics intelligence platform.
"Stateless systems treat every decision in isolation and cannot remember previous incidents or how work actually flows through a site. Stateful’s platform builds a persistent, shared model of tasks, environments and past behaviour that lets robots adapt to disruption and complete missions safely without constant supervision."
Oxford Science Enterprises led the seed round to support expansion across formulation development and data science.
"For decades, the pharmaceutical system has treated approval as the finish line, even though for patients it marks the start of a much longer journey."
The round was led by the Ellison Institute of Technology and will fund research and commercial expansion.
"Advancing agriculture has limitless potential to help people and the planet. So to achieve meaningful, scalable impact, we need the right investors who are truly aligned with that big vision. I’m deeply grateful to EIT and to our current investors for sharing our excitement about what we’ve accomplished so far, and for their united support as we embark on this ambitious growth journey together."
The round was co-led by Oxford Science Enterprises and Cedars-Sinai to accelerate US expansion.
"We’ve spent the last two years proving that remote monitoring can transform neurological care. Clinicians are getting clearer insight without added workload, patients no longer face months of uncertainty between visits, and gain confidence that changes will be recognized rather than missed."
The Oxford spinout secured backing from a group of healthcare investors to scale its EchoGo heart disease detection technology.
"Hospitals already possess the data; they just lack the tools to unlock its full diagnostic potential."
